Facebook
X
LinkedIn
ForwardDate & Time of Session - 10/7/26 - from 2:30 - 3:30 PM
Overview
TA-TMA is a life-threatening complication of hematopoietic stem cell transplantation associated with significant morbidity and mortality. The recent introduction of narsoplimab as the first FDA-approved treatment for TA-TMA has altered the treatment landscape and created a need for healthcare professionals to understand the evolving evidence and therapeutic considerations for this condition.
Objectives
Upon completion of this activity, the participant will be able to:
1. Identify risk factors for TA-TMA
2. Explain the clinical course and diagnostic features of TA-TMA
3. Categorize patients with TA-TMA as low-risk and high-risk
4. Correlate the pathophysiology of TA-TMA with therapeutic targets
5. Evaluate the evidence supporting narsoplimab and eculizumab for TA-TMA
Speakers
Emily R. Puleo, PharmD
PGY2 Oncology Pharmacy Resident
Norton Healthcare – Louisville, Kentucky
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Course JA-UAN Number: JA0000312-9999-26-072-L01-P
- 1.00 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™ Participation
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™ Participation. Learners should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC (UK Healthcare CECentral)
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).
- 1.00 IPCE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.